Reviewing the toolbox for degrader development in oncology

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Targeted protein degradation is an emerging therapeutic modality.
• Bifunctional small-molecule degraders are clinically advanced, with various names including PROTACs, Degronimids, SNIPERs, and uSMITEs.
• Oncology is a primary focus for degrader development, with initial IND filings in 2019.

Purpose of the Study:

• To review the guidelines, reagents, and technologies supporting targeted protein degrader research and development.
• To highlight the advancements in the field of protein degradation, especially for cancer therapy.

Main Methods:

• Literature review of scientific publications and clinical trial data.
• Analysis of the evolving landscape of degrader research tools and technologies.

Main Results:

• The field of targeted protein degradation has rapidly advanced.
• A comprehensive toolbox has been developed to support degrader research.
• Bifunctional degraders show significant promise, particularly in oncology.

Conclusions:

• Targeted protein degradation represents a powerful therapeutic strategy.
• The development of degraders is supported by a growing ecosystem of tools and technologies.
• Further research and development in this area hold significant potential for treating various diseases, especially cancer.